ERS Genomics, Université De Montréal ink CRISPR/Cas9 License Agreement
Overview
ERS Genomics Limited (ERS), the CRISPR licensing company, and Université de Montréal (UdeM), a leading Canadian research institution renowned for scientific innovation and technology transfer, announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants the university access to ERS’ CRISPR/Cas9 patent portfolio – including enabling the launch of two CRISPR/Cas9 screening facility platforms at UdeM’s Institute for Research in Immunology and Cancer.
Statement from Université De Montréal
Lynda Adam, PhD, director of technology transfer, innovation and partnerships, Université de Montréal, said: “With the acquisition of this license, we have launched platform services that will broaden access to genome-wide CRISPR screening and data to the research community. Furthermore, this licence enables UdeM researchers to carry out project collaborations and partnerships using CRISPR technology under certain conditions.”
Words from the CEO: ERS Genomics
John E. Milad, CEO, ERS Genomics, commented: “Université de Montréal has a reputation for making outstanding contributions to scientific innovation. Providing this license and access to the CVC patent portfolio has enabled the launch of screening platforms which will play a role in uncovering new therapeutic targets and ultimately improve healthcare outcomes. We look forward to seeing the transformative impact of their work on global medical challenges.”
About CRISPR Gene Editing
CRISPR gene editing is a genetic engineering technique in molecular biology by which the genomes of living organisms may be modified.
It is based on a simplified version of the bacterial CRISPR-Cas9 antiviral defence system.
The development of the technique earned biochemists Emmanuelle Charpentier (one of the founders of ERS Genomics) and Jennifer Doudna the Nobel Prize in Chemistry in 2020.
ERS Genomics & CRISPR/Cas9 Technology
ERS Genomics provides licensing to CRISPR/Cas9 technology for companies interested in pursuing its use in their commercial programs.
Comprising 100+ patents globally, ERS’ portfolio encompasses CRISPR/Cas9 usage in all cells, including bacteria, archaea, yeasts, and algae.
ERS Genomics licenses these patents via its direct license from Emmanuelle Charpentier and now has nearly 150 licenses in place worldwide.
Financial Details of the Agreement Are Not Disclosed
ERS Genomics provides access to the foundational CRISPR/Cas9 CVC intellectual property held by Dr. Emmanuelle Charpentier, a license to which is essential for freedom to operate commercially with CRISPR/Cas9 technology.
Université De Montréal
Deeply rooted in Montreal and dedicated to its international mission, Université de Montréal is a leading research university worldwide and among the five best French-language universities.
With its affiliated schools, Polytechnique Montréal and HEC Montréal, UdeM attracts over $650 million in research funding every year, making it one of Canada’s top university research hubs.
UdeM has over 67,000 students, 2,300 professors and researchers, and an active global network of 450,000 alumni.